Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 19, 2025 09:00 ET | Source: Palisade Bio, Inc.

Palisade Bio, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

On-demand video webcast now available here Carlsbad, CA, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage...
January 22, 2025 08:00 ET | Source: Palisade Bio, Inc.

Palisade Bio to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar

Live webcast on Wednesday, January 29th at 2:20 PM ET Carlsbad, CA, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a...
November 07, 2024 08:30 ET | Source: Palisade Bio, Inc.

Palisade Bio Announces First Subject Dosed in Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis (UC)

Carlsbad, CA, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade,” “Palisade Bio” or the “Company”), a biopharmaceutical company focused on developing and advancing...
May 01, 2024 08:30 ET | Source: Palisade Bio, Inc.

Palisade Bio’s Lead Product Candidate, PALI-2108 Demonstrates Potent Anti-Inflammatory Effects in Ex-Vivo Study of Whole Blood Samples Challenged with Pro-Inflammatory Lipopolysaccharide (LPS)

Company on track to commence Phase 1 human clinical study of PALI-2108 for the treatment of Ulcerative Colitis (UC) before year end Carlsbad, CA, May 01, 2024 (GLOBE NEWSWIRE) -- Palisade...
December 07, 2022 08:35 ET | Source: Palisade Bio, Inc.

Palisade Bio Announces Early Exercise of Warrants Resulting in Cash Proceeds of $1.25 Million

Proceeds extend cash runway to fund operations into early 2024 Carlsbad, CA, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company...
October 11, 2022 09:25 ET | Source: Palisade Bio, Inc.

Palisade Bio Announces Executive Leadership Transition

Board Appoints JD Finley to Interim Chief Executive Officer Carlsbad, CA, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company...